cevostamab in rrmm patients: camma 2 study results | joshua richter, md | eha 2024
Published 2 weeks ago • 59 plays • Length 2:25
Download video MP4
Download video MP3
Similar videos
-
2:31
asco/eha 2024 myeloma highlights- imroz, dreamm-7, dreamm-8 | joshua richter, md | eha 2024
-
2:18
t cell re-direction therapy | joshua richter, md | eha 2022
-
58:19
sequencing bcma myeloma therapies
-
1:07:46
healthtree podcast for myeloma: joshua richter, md, mount sinai covid update
-
2:06
safety & efficacy of cevostamab in patients with heavily pre-treated r/r multiple myeloma
-
3:11
bispecific antibodies | joshua richter, md | ash 2022
-
2:18
preventing and monitoring infections with immune therapies | joshua richter, md | ims 2023
-
31:04
thriving with myeloma: what you should know about care and treatment
-
22:52
haematological emergencies
-
4:37
multiple myeloma precursor conditions | high impact topic (hit)
-
1:02
outcomes of patients with myeloma receiving fixed-duration cevostamab
-
57:58
how often should mrd testing occur during remission (and an mrd overview) with dr. joshua richter
-
1:25
safety and efficacy of linvoseltamab for patients with r/r multiple myeloma
-
10:16
selinexor in multiple myeloma — dr. joshua richter | mcrt webcast july 11
-
7:18
response rate on phase 1/2 trial regn5458 (bcmaxcd3 bispecific antibody) for rrmm patients
-
1:53
istopmm study and early mgus and smm screening | joshua richter, md | ash 2021
-
1:28
regeneron bispecific antibody targeting bcma update | joshua richter, md | ash 2021
-
2:01
dr. joshua richter discusses multiple myeloma clinical trials
-
1:47
insights into the efficacy of linvoseltamab in the treatment of r/r multiple myeloma
-
1:33
updates from the linker-mm1 study: linvoseltamab in r/r multiple myeloma
-
5:20
what are bispecifics in multiple myeloma? (for patients and caregivers) | dr. joshua richter
Clip.africa.com - Privacy-policy